ALVR107: An allogeneic, off-the-shelf virus-specific T cell (VST) therapy candidate targeting the Hepatitis B virus


Unmet Treatment Needs for Chronic Hepatitis B

The global prevalence of HBV is estimated to be between 292 and 360 million, with approximately 260 million people living with chronic HBV infection.

Current treatment options for chronic HBV consist of life-long antiviral therapy to suppress virus replication. This can slow the progression of liver cirrhosis and reduce the incidence of liver cancer. About 30% of patients with chronic HBV develop liver cirrhosis, and nearly 23% of these die within five years of developing cirrhosis. Despite long-term antiviral therapy, 16.2% and 9.3% progressed to cirrhosis and developed HCC at 5 years, respectively.

HBV is most common in the Western Pacific and African regions, where approximately 6% of the adult population is infected.

Only approximately 1.6% and 0.7% of the European and Americas regions, respectively, are infected.

Chronic HBV Infection

Chronic HBV infection is associated not only with significant morbidity and mortality, but also with weak or absent endogenous HBV-specific T cell reactivity. In contrast, clinical recovery and effective antiviral therapy are associated with sustained viral control by HBV-specific T cells.

Currently, there are no curative therapies available.

Development Plan

ALVR107 is in preclinical development with plans to commence Phase 1/2 clinical trials.

Our Pipeline

Our allogeneic, off-the-shelf VST therapy candidates target 12 different devastating viruses to treat and prevent life-threatening viral diseases.

Expanded Access

Read our expanded access policy.

AlloVir is the Global Leader in Developing VST Immunotherapies

We develop highly innovative allogeneic, off-the-shelf VST therapy candidates designed to treat or prevent devastating viral infections and diseases.

Our Pipeline

Our allogeneic, off-the-shelf, VST therapy candidates target 12 different devastating viruses to treat or prevent life-threatening viral diseases.

Our Platform

Our proprietary platform develops allogeneic, off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies.

Our People

Our founders have a singular vision: to serve patients at risk of the devastating consequences of severe viral infections and diseases.